Evotec SE and Indivumed GmbH have entered into a new research collaboration to discover and develop first-in-class therapeutics for the treatment of non-small cell lung cancer (NSCLC). The goal of this precision medicine collaboration is to deliver highly effective treatments for NSCLC patients. The collaboration will combine Evotec’s bioinformatics analysis platform “PanHunter,” as well as its small molecule and antibody discovery platforms, with the NSCLC cohort of Indivum...